With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern
(VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 …

Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune
monitoring (CAPTURE)(NCT03226886) is a prospective cohort study of COVID-19 immunity …

Background Available data show that COVID-19 vaccines may be less effective in
immunocompromised populations, who are at increased risk of severe COVID-19 …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …

Background B-cell-depleting therapies increase the risk of morbidity and mortality due to
COVID-19. Evidence-based SARS-CoV-2 vaccination strategies for patients on B-cell …

Despite vaccination and antiviral therapies, immunocompromised individuals are at risk for
prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but the …

We aim to evaluate the evolution differences in the incidence and case fatality rate (CFR) of
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Delta and Omicron …

The coronavirus infectious disease (COVID-19) shows a remarkable symptomatic
heterogeneity. Several risk factors including advanced age, previous illnesses, and a …

Background Patients with cancer are considered a priority group for Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination given their high risk of …